


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-93. (Cancelled)

94. (Currently Amended) An ANT ligand having the following structure:



and stereoisomers and pharmaceutically acceptable salts thereof,

wherein

R<sub>1</sub> is ~~hydroxyl~~, halogen, -OC(=O)R<sub>4</sub> or -NHR<sub>4</sub>;

R<sub>2</sub> is hydrogen or -C(=O)R<sub>5</sub>;

R<sub>3</sub> is -CH<sub>3</sub> or =CH<sub>2</sub>;

R<sub>4</sub> is ~~-X-aryl~~, ~~-X-substituted-aryl~~, -X-arylalkyl, -X-substituted arylalkyl, X-heteroaryl, or -X-heteroarylalkyl, wherein X is an optional amido or alkylamido linker moiety; and

R<sub>5</sub> is alkyl.

95. (Cancelled)

96. (Currently Amended) The ANT ligand of claim 94 wherein  $R_1$  is  $-\underline{O}C(=O)R_4$ .

97. (Withdrawn) The ANT ligand of claim 94 wherein  $R_1$  is  $-NHR_4$ .

98. (Original) The ANT ligand of claim 94 wherein  $R_2$  is hydrogen.

99. (Original) The ANT ligand of claim 94 wherein  $R_2$  is  $-C(=O)R_5$ .

100. (Original) The ANT ligand of claim 94 wherein  $R_3$  is  $-CH_3$ .

101. (Original) The ANT ligand of claim 94 wherein  $R_3$  is  $=CH_2$ .

102. (Currently Amended) The ANT ligand of claim 94 wherein  $R_4$  is  $-\underline{X}$ -aryl,  ~~$-\underline{X}$ -substituted aryl,~~  $-\underline{X}$ -arylalkyl or  $-\underline{X}$ -substituted arylalkyl.

103-107. (Cancelled)

108. (Original) A pharmaceutical composition comprising an ANT ligand of claim 94.

109-112. (Cancelled)